Due to advances in cancer immunotherapy, including positive results from clinical trials testing new agents and combinations, emerging technologies for measuring different facets of immunity, and novel candidate biomarkers, the SITC Immune Biomarkers Oversight Committee has reconvened to review state of the art technologies, identify current hurdles to further success and to make recommendations to the field.The committee provides expert guidance and insights on the state of the art regarding biomarker identification and application in cancer immunotherapy to more rapidly move the field forward. Central points of focus include biomarker standardization, validation, and identification, as well as data and specimen sharing, collaboration across disciplines, and emergent technologies for investigation of novel candidate biomarkers from early phase trials.
In the video below, published by OncLive, SITC Immediate Past President Lisa H. Butterfield, PhD, discusses the SITC Immune Biomarkers Committee.
The SITC Immune Biomarkers Oversight Committee reconvened on May 16-17, 2018 for a two-day workshop on critical next steps in the field, including:
A review of this meeting was published in the Journal for ImmunoTherapy of Cancer (JITC) on Dec. 4, 2018.
Enduring materials from this program are available to the general public. Click here to access the presentations. Presentations and video recordings are available based on permission from presenters.
NCI/CCR and SITC co-sponsored a 2016 biomarkers meeting to review the state of the art, discuss current hurdles to further success, and consider recommendations to move the field forward.The main goals were to provide updated information to a wide audience and solicit stakeholder participation in promoting successful immune biomarker research.
A review of this meeting was published in the Journal for ImmunoTherapy of Cancer (JITC) in March 2017.
Validation of Biomarkers to Predict Response to Immunotherapy in Cancer (two-part white paper) Journal for ImmunoTherapy of Cancer, November 2016
Novel technologies and emerging biomarkers for personalized cancer immunotherapy Journal for ImmunoTherapy of Cancer, January 2016
Systematic evaluation of immune regulation and modulation Journal for ImmunoTherapy of Cancer, March 2017
Identifying baseline immune-related biomarkers to predict clinical outcome of immunotherapy Journal for ImmunoTherapy of Cancer, May 2017
Click here to view a complete list of current and past published Immune Monitoring Technology Primers in the Journal for ImmunoTherapy of Cancer (JITC).
SITC/iSBTc Cancer Immunotherapy Biomarkers Resource Document: Online resources and useful tools – a compass in the land of biomarker discovery Journal of Translational Medicine, September 2011Recommendations from the iSBTc-SITC/FDA/NCI Workshop on Immunotherapy Biomarkers Clinical Cancer Research, May 2011Immuno-Oncology biomarkers 2010 and beyond: Perspectives from the iSBTc/SITC biomarker task force Journal of Translational Medicine, December 2010A systematic approach to biomarker discovery; Preamble to "the iSBTc-FDA taskforce on immunotherapy biomarkers" Journal of Translational Medicine, December 2008Workshop on Cancer Biometrics: Identifying Biomarkers and Surrogates of Cancer in Patients Journal of Immunotherapy, March/April 2005Immunologic Monitoring of Cancer Vaccine Therapy: Results of a Workshop Sponsored by the Society for Biological Therapy Journal of Immunotherapy, March/April 2002
The following are the currently active subcommittees of the SITC Immune Biomarkers Committee and their purpose:
PURPOSE: The Data Sharing Subcommittee provides expert guidance and insights on the management, analysis, and sharing of biomarker data and resources between diverse organizations in the cancer immunotherapy setting.CHAIRAlessandra Cesano, MD, PhDESSA Pharma Inc.CO-CHAIRSergio Rutella, MD, PhD, FRCPathThe John Van Geest Cancer Research Center
PURPOSE: The Microbiome Subcommittee provides expert guidance and insights on best practices and recommendations regarding microbiome research for application in the cancer immunotherapy setting.CHAIRJennifer A. Wargo, MD, MMScThe University of Texas MD Anderson Cancer CenterCO-CHAIRLaurence Zitvogel, MD, PhDInstitute Gustave Roussy
PURPOSE: The Resources & Useful Tools Subcommittee provides expert guidance and insights on the latest technologies and resources available, or soon to be available for biomarker identification and validation to advance cancer immunotherapies.CHAIRHolden T. Maecker, PhDStanford UniversityCO-CHAIRSiwen Hu-Lieskovan, MD, PhDUniversity of Utah
PURPOSE: The Tumor Mutational Burden (TMB) Subcommittee provides expert guidance and recommendations regarding scientific biology, technologies and practices relating to TMB as a quantitative genomic biomarker for personalized medicine in the cancer immunotherapy setting.CHAIRJianda Yuan, MD, PhMerck Research LaboratoriesCO-CHAIRPriti S. Hegde, PhDGenentech, Inc.
Lisa H. Butterfield, PhD PICI Research Center, Parker Institute for Cancer Immunotherapy; University of California, San Francisco
Mary L. Disis, MD University of Washington
Raj K. Puri, MD, PhD U.S. Food and Drug Administration
Tel: +1 414 271 2456 | Fax: +1 414 276 3349 | Email: firstname.lastname@example.org